Prevention of infection in cancer patients.
Patients with cancer vary regarding the nature and level of immunocompromise. Both the underlying malignancy and therapy can influence risk of infectious complications. Therefore, decisions about antimicrobial prophylaxis must be guided by a number of factors: (1) the risk of infection; (2) the potential severity of infection and the likelihood of response to therapy; and (3) the safety and efficacy of antimicrobial prophylaxis. The potential for selection for antibiotic-resistant pathogens should also inform decisions about prophylaxis. When assessing clinical trial data on antimicrobial prophylaxis, two major criteria should be considered: the quality of studies supporting prophylaxis (randomized, blinded studies are optimal) and the expected benefit of prophylaxis, measured in terms of prevention of morbidity and potentially mortality. This chapter reviews the epidemiology and clinical trial data on prophylaxis against the major bacterial, viral, and fungal diseases in patients with cancer. Gaps in knowledge and alternative approaches, such as the use of newer diagnostics, are discussed.
School of Medicine and Biomedical Sciences, University of Buffalo School of Medicine, Buffalo, NY, USA.
Diana
D
Pomakova
Brahm H
BH
Segal
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006801:Humans; D017053:Infection Control; D009369:Neoplasms / Q000150:complications*; D009894:Opportunistic Infections / Q000517:prevention & control*; D012307:Risk Factors
D000890:Anti-Infective Agents